Precision Medicine Online provides the latest news for healthcare leaders and scientists interested in precision medicine and individualized approaches to treatment and prevention.

2025年1月31日 · During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

2024年10月9日 · Reimbursement news and insurance coverage updates from Precision Medicine Online.

2025年1月6日 · NEW YORK – The US Food and Drug Administration in 2024 approved dozens of new and expanded precision medicine indications. Although most of these approvals were still in cancer and rare conditions, the field of precision medicine is poised to enter bigger markets for Alzheimer's, heart, and autoimmune diseases that could better patients' lives — if they can afford and access them.

5 天之前 · NEW YORK – Currently available large language models (LLMs) are not accurate enough to use safely for clinical decision support, but physician-scientists are continuing to test artificial intelligence (AI)-driven chatbots to better understand their limits when used to navigate complex precision oncology treatment options.

2024年12月30日 · NEW YORK – In 2024, Precision Medicine Online readers were most interested in stories tracking the implementation of personalized treatments and tests for cancer, cardiovascular disease, and rare conditions. An annual survey tracking the investments US cancer centers and hospitals are making in precision …

2025年2月4日 · NEW YORK – Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and antibody-drug conjugate franchises alongside potential financial impacts from the US Inflation Reduction Act (IRA). The firm's oncology business had Q4 revenues ...

2024年12月19日 · NEW YORK – The use of artificial intelligence in precision medicine research and development surged in 2024 as researchers in industry and academia explored ways to leverage the technology to improve cancer diagnoses, predict …

2025年1月8日 · NEW YORK – In the biomarker-targeted treatment space, experts are anticipating more research in 2025 that will further refine patient selection and are expecting continued advancement of next-generation precision therapies, including antibody-drug conjugates (ADCs), cancer vaccines, and protein degraders.